Two patients with acute intermittent porphyria treated with nafarelin to prevent menstrual exacerbations

Elder GH , Hift RJ , Meissner PN. The acute porphyrias. Lancet 1997; 349: 1613–17

Anderson KE , Spitz IM , Sassa S , Bardin CW , Kappas A. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med 1984; 311: 643–5

Johansen JS , Riis BJ , Hassager C The effect of gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988; 67: 701–6

Milan R , Henzel MR. Gonadotropin-releasing hormone analogs: update on new findings. Am J Obstet Gynecol 1992; 166: 757–61

Riis BJ , Christiansen C , Johansen JS , Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 1990; 70: 920–4

Chrisp P , Goa KL. Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs 1990; 39: 523–51